durvalumab,serplulimab,Carboplatin,Atezolizumab,Etoposide
astrazeneca,fosun pharmaceuticals,roche
['caspian', 'serplulimab', 'sclc']
#asco22 ph 3 astrum-005 study serplulimab (anti-pd1) chemo v chemo in es sclc
- mos 15.4 v 10.9m (hr 0.63) p&lt;0.001
- benefit across all subsets another chemo-io option in es sclc, unclear if chemo-pdl1 (impower133, caspian) or chemo-pd1 is best in es sclc 
Thoracic Oncologist focused on immunotherapy for lung cancer & immune toxicity. Beaumont RCSI Cancer Centre Dublin; Adjunct Asst Prof Johns Hopkins University